Company Overview and News
Earnings: Power Grid Corporation has reported 4.6 percent rise in its Q4FY18 net profit at Rs 2,004.7 crore against Rs 1,916.4 crore in the same quarter last fiscal.
500325 RELIANCE 532712 533278 STAR RCOM 532483 RIGD GODFRYPHLP HDFCBANK CLNDY RLNIY BANKINDIA IBN 532967 538835 KIRIINDUS DCMSRMIND 532941 532149 BHEL CNRYY 532531 ICICIBANK CORDSCABLE HDB 532174 500180 BRHTY INTELLECT 500103 534809 PCJEWELLER 500163 CANBK 523369 COALINDIA
New Delhi: Drug firm Strides Shasun has sought shareholders’ nod to change its name to Strides Pharma Science. This is the second time in three years time, when the name of the company will change.
Earnings Reaction: Godfrey Phillips India's March quarter profit dropped 22.8 percent year-on-year to Rs 43.1 crore and revenue from operations declined 37.6 percent to Rs 543.3 crore.
500325 RELIANCE 532955 532712 STAR RCOM RIGD GODFRYPHLP HDFCBANK RLNIY BANKINDIA IBN 538835 DCMSRMIND 532941 532149 BHEL 539207 532531 ICICIBANK CORDSCABLE HDB 532174 500180 BRHTY INTELLECT 500103 RECLTD 500163 523369 MANPASAND
Earnings: M&M's March quarter earnings beat analyst expectations as profit grew by 50 percent year-on-year to Rs 1,155 crore and revenue increased 25.6 percent to Rs 13,189 crore during the quarter.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD HDFCBANK RLNIY BANKINDIA 524804 IBN 538835 532941 532149 BHEL 539207 532531 ICICIBANK CORDSCABLE HDB 532174 500180 ARBQY BRHTY INTELLECT 500103 RECLTD MANPASAND
Market Update: Benchmark indices as well as broader markets are in a consolidation mode after sharp rally seen in previous three consecutive sessions. Investors closely monitor the movement in crude oil prices and rupee.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD 519183 GREENPLY HDFCBANK RLNIY IPCALAB 524804 IBN 538835 BHEL 539207 532531 ICICIBANK 524494 HDB 532174 500180 ARBQY 526797 BRHTY INTELLECT 500103 RECLTD MANPASAND ADFFOODS
Drug firm Strides Shasun has sought shareholders' nod to change its name to Strides Pharma Science. This is the second time in three years time, when the name of the company will change.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to NSE:STAR / STRIDES ARCOLAB LTD. on message board site Silicon Investor.